Bull case
Enliven Therapeutics is viewed favorably because ELVN-001 has shown compelling Phase 1 ENABLE efficacy in heavily pretreated CML, with a 61% overall major molecular response at 24 weeks in the 80 mg cohort and meaningful deep molecular responses, suggesting strong activity even after multiple prior TKIs and prior asciminib or ponatinib exposure. The data also support a differentiated competitive profile across lines of therapy, as ELVN-001 achieved 55%, 32%, and 29% MMR rates by 24 weeks in evaluable patients with 1-2, 3-4, and 5+ prior unique TKIs, respectively, strengthening confidence in its broader addressable market. Combined with the company’s positive read-through from EHA 2026 and the recent equity offering, the outlook is reinforced by a higher estimated probability of approval in the 2L+ setting and a pipeline that also includes ELVN-002 against HER2 mutations.